INHIBIKASE THERAPEUTICS INC (IKT) Stock Price & Overview
NASDAQ:IKT • US45719W2052
Current stock price
The current stock price of IKT is 1.89 USD. Today IKT is up by 0.53%. In the past month the price increased by 12.5%. In the past year, price decreased by -16%.
IKT Key Statistics
- Market Cap
- 249.537M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.50
- Dividend Yield
- N/A
IKT Stock Performance
IKT Stock Chart
IKT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to IKT. When comparing the yearly performance of all stocks, IKT turns out to be only a medium performer in the overall market: it outperformed 49.34% of all stocks.
IKT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IKT. No worries on liquidiy or solvency for IKT as it has an excellent financial health rating, but there are worries on the profitability.
IKT Earnings
IKT Forecast & Estimates
12 analysts have analysed IKT and the average price target is 5.87 USD. This implies a price increase of 210.32% is expected in the next year compared to the current price of 1.89.
IKT Groups
Sector & Classification
IKT Financial Highlights
Over the last trailing twelve months IKT reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 80.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.87% | ||
| ROE | -65.37% | ||
| Debt/Equity | 0 |
IKT Ownership
IKT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.31 | 351.47B | ||
| AMGN | AMGEN INC | 14.9 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.45 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.87 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.88 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.2 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.21 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.4 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.37 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IKT
Company Profile
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 15 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Company Info
IPO: 2020-12-23
INHIBIKASE THERAPEUTICS INC
1000 N. West Street, Suite 1200
Wilmington DELAWARE 30339 US
CEO: Milton H. Werner
Employees: 35
Phone: 13022953800
INHIBIKASE THERAPEUTICS INC / IKT FAQ
What does INHIBIKASE THERAPEUTICS INC do?
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 15 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
What is the stock price of INHIBIKASE THERAPEUTICS INC today?
The current stock price of IKT is 1.89 USD. The price increased by 0.53% in the last trading session.
Does INHIBIKASE THERAPEUTICS INC pay dividends?
IKT does not pay a dividend.
What is the ChartMill technical and fundamental rating of IKT stock?
IKT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for IKT stock?
12 analysts have analysed IKT and the average price target is 5.87 USD. This implies a price increase of 210.32% is expected in the next year compared to the current price of 1.89.
What is the Price/Earnings (PE) ratio of INHIBIKASE THERAPEUTICS INC (IKT)?
INHIBIKASE THERAPEUTICS INC (IKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
Can you provide the upcoming earnings date for INHIBIKASE THERAPEUTICS INC?
INHIBIKASE THERAPEUTICS INC (IKT) will report earnings on 2026-05-12.